{"id":69688,"date":"2025-08-15T20:47:18","date_gmt":"2025-08-15T20:47:18","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/69688\/"},"modified":"2025-08-15T20:47:18","modified_gmt":"2025-08-15T20:47:18","slug":"outdated-guidance-sees-thousands-at-risk-of-prostate-cancer-overtreatment","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/69688\/","title":{"rendered":"\u2018Outdated guidance\u2019 sees thousands at risk of prostate cancer \u2018overtreatment\u2019"},"content":{"rendered":"<p class=\"paragraph-text\">Overtreatment of the disease can lead to side effects such as erectile dysfunction or incontinence, according to Prostate Cancer UK.<\/p>\n<p class=\"paragraph-text\">Experts suggest closely monitoring certain patients can be the &#8220;best&#8221; option for men whose cancer is unlikely to progress, although out-of-date guidance from the National Institute of Health and Care Excellence (Nice) on how this is implemented has created a &#8220;wild west&#8221;.<\/p>\n<p class=\"paragraph-text\">There are around 55,000 new cases of prostate cancer diagnosed in the UK every year.<\/p>\n<p class=\"paragraph-text\">However, in some cases, the cancer is slow-growing and unlikely to ever cause the patient harm.<\/p>\n<p class=\"paragraph-text\">These men benefit from being closely monitored with blood tests and scans, which is known as active surveillance.<\/p>\n<p class=\"paragraph-text\">Nice guidance on active surveillance is designed to advise specialists on how to implement monitoring and which men should be monitored.<\/p>\n<p class=\"paragraph-text\">However, it has not been updated since 2021, according to Prostate Cancer UK.<\/p>\n<p class=\"paragraph-text\">Freedom of information (FOI) request analysis by the charity found around one in four (24%) of hospitals rely on Nice guidance alone to implement active surveillance.<\/p>\n<p class=\"paragraph-text\">It also found 35 hospitals have created their own guidelines, which Prostate Cancer UK warned can lead to inconsistency and confusion among medics.<\/p>\n<p class=\"paragraph-text\">The charity is now repeating its call for Nice to update its guidance on active surveillance, claiming it could help up to 5,000 men a year avoid overtreatment.<\/p>\n<p class=\"paragraph-text\">Read more: <a href=\"https:\/\/www.lbc.co.uk\/news\/health\/nhs-england-labour-redundancy-payoff\/\" rel=\"nofollow noopener\" target=\"_blank\">Labour plan to reform NHS plunged into chaos by &#8216;\u00a31bn redundancy payoff&#8217;<\/a><\/p>\n<p class=\"paragraph-text\">Read more: <a href=\"https:\/\/www.lbc.co.uk\/news\/uk\/nurses-violence-nhs-streeting\/\" rel=\"nofollow noopener\" target=\"_blank\">Nurses facing \u2018abhorrent\u2019 violence levels while in A&amp;E<\/a><\/p>\n<p class=\"paragraph-text\">It also claims the outdated guidance is hindering a screening programme for prostate cancer.<\/p>\n<p class=\"paragraph-text\">Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: &#8220;To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment but official guidelines still haven\u2019t caught up with the clinical evidence.<\/p>\n<p class=\"paragraph-text\">&#8220;Concerns about overtreatment are a major reason the UK does not routinely screen for prostate cancer, despite it being the most common cancer in England.<\/p>\n<p class=\"paragraph-text\">&#8220;Acting on latest research that shows more men can safely opt for monitoring instead of treatment will reduce overtreatment and the harm it causes men.<\/p>\n<p class=\"paragraph-text\">&#8220;We asked Nice to update their active surveillance guidance two years ago, but our request was rejected. Now we have evidence this is potentially affecting thousands of men. Enough is enough.&#8221;<\/p>\n<p class=\"paragraph-text\">The NHS uses a prostate-specific antigen (PSA) blood test to check for prostate conditions including prostate cancer or an enlarged prostate.<\/p>\n<p class=\"paragraph-text\">Routine PSA testing is not currently offered on the NHS, but patients may be offered a PSA test if a GP suspects they have prostate cancer, while men over 50 can request a test from their GP even if they do not have symptoms.<\/p>\n<p class=\"paragraph-text\">However, there have been calls to roll the test out across the health service, although some argue widespread use could identify cases which may not have caused problems or needed treatment.<\/p>\n<p class=\"paragraph-text\">Vincent Gnanapragasam, a professor of urology at the University of Cambridge, said: &#8220;Active surveillance is the best treatment option for men whose cancer is unlikely to progress or cause them problems in their lifetime.<\/p>\n<p class=\"paragraph-text\">&#8220;But Nice\u2019s outdated guidelines have created a deeply concerning wild west on how surveillance is implemented by different healthcare teams.<\/p>\n<p class=\"paragraph-text\">&#8220;This inconsistency is resulting in a lack of confidence from patients in surveillance, who may instead opt to have treatment they may not have ever needed, risking harmful side effects.<\/p>\n<p class=\"paragraph-text\">&#8220;Programmes for active surveillance that are standardised and individualised to a man\u2019s risk factors have been tested and proven to work.&#8221;<\/p>\n<p class=\"paragraph-text\">The UK\u2019s National Screening Committee is currently assessing whether a national screening programme for prostate cancer should be rolled out.<\/p>\n<p class=\"paragraph-text\">A Nice spokesperson said: &#8220;We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes.<\/p>\n<p class=\"paragraph-text\">&#8220;They are developed by an independent committee, including NHS clinical experts, and are kept under review to ensure they remain current.<\/p>\n<p class=\"paragraph-text\">&#8220;We are updating our prostate cancer guideline, including a review of the recommendations around active surveillance, and will be assessing whether our suspected cancer guideline recommendations around age-related thresholds for PSA tests for prostate cancer for onwards referral from primary care require updating.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"Overtreatment of the disease can lead to side effects such as erectile dysfunction or incontinence, according to Prostate&hellip;\n","protected":false},"author":2,"featured_media":69689,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[102,2960,56,54,55],"class_list":{"0":"post-69688","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-uk","11":"tag-united-kingdom","12":"tag-unitedkingdom"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/69688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=69688"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/69688\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/69689"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=69688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=69688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=69688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}